Mallory Price
Acute Care · Baton Rouge, LANPI 1215607635
Payments from drug & device makers
What this record shows
20 manufacturers reported payments, led by United Therapeutics Corporation at 57.4% of the total. Reporting peaked in 2023 at $2,110 and has fallen 71.2% since, to $607 in 2024.
Across 64 payments — averaging $43.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$2K
- Actelion Pharmaceuticals US, Inc.$267
- AstraZeneca$109
- Merck$109
- Regeneron Healthcare Solutions, Inc.$84
- GSK$83
- plus $547 from 14 others
What the payments were for
- Travel & lodging$1,24744%
- Food & beverage$1,56856%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 10 | $1,615 |
| Actelion Pharmaceuticals US, Inc. | 7 | $267 |
| AstraZeneca | 6 | $109 |
| Merck | 5 | $109 |
| Regeneron Healthcare Solutions, Inc. | 4 | $84 |
| GSK | 5 | $83 |
| Mylan Specialty L.p. | 4 | $83 |
| Sanofi | 3 | $82 |
| Baxter Healthcare | 4 | $74 |
| Insmed, Inc. | 2 | $46 |
| Bayer | 3 | $46 |
| Tactile Systems Technology Inc | 1 | $39 |
| Grifols USA, LLC | 2 | $37 |
| AbbVie | 2 | $31 |
| Boehringer Ingelheim | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Philips North America LLC | 1 | $16 |
How this compares
$2,815 in reported general payments places this provider in the 80th percentile of 248 acute care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 23 | $235,204 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 163 | $125,878 |
| Breo ElliptaFluticasone/Vilanterol | 145 | $70,072 |
| NucalaMepolizumab | 11 | $40,193 |
| Tadalafil | 14 | $23,809 |
| Spiriva RespimatTiotropium Bromide | 29 | $22,029 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $21,548 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $14,812 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,422 |
| Arnuity ElliptaFluticasone Furoate | 20 | $5,796 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $5,497 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,400 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $2,964 |
| Azithromycin | 99 | $1,436 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $19 | $278,78188 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta | $83 | $248,361353 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $109 | $19,21227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 248 acute care providers in Louisiana.
Other acute care in Baton Rouge
- Chad KlugBaton Rouge$8K
- Emily BurkeBaton Rouge$6K
- Precious HodgesLafayette$70K
- Brinton FegleyShreveport$61K
- Charles JarreauNew Orleans$40K
- Jeremy DavisShreveport$35K
- Heather MecomShreveport$17K
- Jeremy TerroLafayette$11K
- Mary HireShreveport$11K
- Jacquelyn CosterHouma$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.